Literature DB >> 7924475

Treatment of acute asthma. Lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer.

C Rodrigo1, G Rodrigo.   

Abstract

We conducted a randomized, double-blind, placebo-controlled study to determine if intravenous aminophylline adds any benefit to high doses of inhaled salbutamol in patients who presented for treatment of acute asthma. We studied 94 patients (mean age, 35.6 +/- 11.2 years) with moderate to severe acute asthma. All patients received therapy with salbutamol delivered with metered-dose inhaler (MDI) into a spacer device (Volumatic) in four puffs (400 micrograms) at 10-min interval, and intravenous hydrocortisone (500 mg). Patients were randomly assigned to receive either a loading dose of intravenous aminophylline followed by a routine infusion (n = 45) or an equal volume of placebo as a loading dose and infusion (n = 49). The two groups showed no differences in measurements of peak expiratory flow, FEV1, and FVC at baseline and at the end of treatment. However, the patients treated with aminophylline had significantly more adverse effects (p < 0.05). There were no differences in the final mean dose of salbutamol (6.3 +/- 44.5 mg for the placebo group and 5.8 +/- 4.2 mg for the aminophylline group), hospital admission rate (10.2 percent for the placebo group and 9.0 percent for the aminophylline group), and mean duration of Emergency Department treatment (2.5 +/- 1.83 h for the placebo group and 2.37 +/- 1.75 h for the aminophylline group). The results were similar when the patients were divided in accord with the degree of respiratory obstruction (baseline FEV1 < 30 percent of predicted) and theophylline level at 30 min of treatment (placebo group patients with theophylline level < 10 mg/L vs aminophylline group patients with theophylline level > or = 10 mg/L). We conclude that intravenous aminophylline adds to the toxicity but not the efficacy of inhaled salbutamol in the treatment of acute exacerbations of asthma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7924475     DOI: 10.1378/chest.106.4.1071

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Pharmacologic management of the hospitalized pediatric asthma patient.

Authors:  K A Hardin; H J Kallas; R J McDonald
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

2.  Management of severe asthma exacerbation in children.

Authors:  Xiao-Fang Wang; Jian-Guo Hong
Journal:  World J Pediatr       Date:  2011-10-20       Impact factor: 2.764

3.  Study on airway smooth muscle tone using fiberoptic bronchoscopy: basic research and clinical application.

Authors:  Kazuyoshi Hirota
Journal:  J Anesth       Date:  2010-12-28       Impact factor: 2.078

Review 4.  Management of acute asthma in adults in the emergency department: nonventilatory management.

Authors:  Rick Hodder; M Diane Lougheed; Brian H Rowe; J Mark FitzGerald; Alan G Kaplan; R Andrew McIvor
Journal:  CMAJ       Date:  2009-10-26       Impact factor: 8.262

Review 5.  Addition of intravenous aminophylline to inhaled beta(2)-agonists in adults with acute asthma.

Authors:  Parameswaran Nair; Stephen J Milan; Brian H Rowe
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

6.  Randomised controlled trial of aminophylline for severe acute asthma.

Authors:  M Yung; M South
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

7.  Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial.

Authors:  G Roberts; D Newsom; K Gomez; A Raffles; S Saglani; J Begent; P Lachman; K Sloper; R Buchdahl; A Habel
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

Review 8.  The pulmonary physician in critical care . 12: Acute severe asthma in the intensive care unit.

Authors:  P Phipps; C S Garrard
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

Review 9.  Clinical review: severe asthma.

Authors:  Spyros Papiris; Anastasia Kotanidou; Katerina Malagari; Charis Roussos
Journal:  Crit Care       Date:  2001-11-22       Impact factor: 9.097

Review 10.  Efficacy and side effects of intravenous theophylline in acute asthma: a systematic review and meta-analysis.

Authors:  Gulixian Mahemuti; Hui Zhang; Jing Li; Nueramina Tieliwaerdi; Lili Ren
Journal:  Drug Des Devel Ther       Date:  2018-01-10       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.